Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Background Linezolid is a bacteriostatic oxazolidinone antibiotic that has been proven to be effective for the treatment of patients with pneumonia, skin and soft tissue infections, and possibly bacteraemia, due to Gram-positive cocci. However, the drug is sometimes used for the treatment of patients with endocarditis due to Gram-positive cocci resistant to other antibiotics. Methods We carried out a review of the available literature to evaluate whether linezolid is also effective for the treatment of patients with infective endocarditis. Results We identified 23 case reports and 3 case series reporting the experience with 56 patients with endocarditis treated with linezolid. Evaluable data for 33 patients who received linezolid and for whom individual patient data were reported were further analysed. Prosthetic valve infective endocarditis accounted for 25% of the reviewed cases. Methicillin-resistant Staphylococcus aureus and vancomycin-intermediate S. aureus were the most commonly isolated cocci (24.2% and 30.3% of cases, respectively). Linezolid alone was administered to 66.7% of patients while the rest received the antibiotic in combination with rifampicin, gentamicin, fusidic acid or amikacin. A total of 63.6% (21/33) of patients with endocarditis were cured after linezolid administration. The overall and endocarditis-related mortality was 33.3% (11/33) and 12.1% (4/33), respectively. Thrombocytopenia developed in 30.8% (8/26) of patients for whom relevant data were av…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a small number of patients, linezolid was effective therapy of vancomycin-resistant E faecium IE. 174”
Citations
Cites
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.165564 · Cited by 1,707
Infective Endocarditis in Adults
Mylonakis, E., & Calderwood, S. B. (2001) · New England Journal of Medicine · doi:10.1056/nejmra010082 · Cited by 1,324
Moreillon, P., & Que, Y.-A. (2004) · The Lancet · doi:10.1016/s0140-6736(03)15266-x · Cited by 861
Howden, B. P., Ward, P. B., Charles, P. G. P., Korman, T. M., Fuller, A., Cros, P. D., Grabsch, E. A., Roberts, S. A., Robson, J., Read, K., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/381202 · Cited by 484 · cited 2×
“2006 (4) M 46 RA, AV and MV replacement possible abscess in the mitral-aortic area CoNS VAN, RIF ( 15 ),”
Birmingham, M. C., Rayner, C. R., Meagher, A. K., Flavin, S. M., Batts, D. H., & Schentag, J. J. (2003) · Clinical Infectious Diseases · doi:10.1086/345744 · Cited by 428
Management of infective endocarditis
Habib, G. (2006) · Heart · doi:10.1136/hrt.2005.063719 · Cited by 211
Shorr, A. F., Kunkel, M. J., & Kollef, M. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki355 · Cited by 198 · cited 1×
“M 67 DM prosthetic AV VISA VAN ( 32 ) NA 42 died NA none”
Chien, J. W., Kucia, M. L., & Salata, R. A. (2000) · Clinical Infectious Diseases · doi:10.1086/313597 · Cited by 190 · cited 1×
“2000 ( 27 ) NA abdominal aortic repair, DM, ARF NA VRE VAN, ALF (NA) NA 42 cure 1 none”
Rubinstein, E., Isturiz, R., Standiford, H. C., Smith, L. G., Oliphant, T. H., Cammarata, S., Hafkin, B., Le, V., & Remington, J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.6.1824-1831.2003 · Cited by 177
Successful Treatment of Vancomycin-Resistant Enterococcus Endocarditis with Oral Linezolid
Babcock, H. M., Ritchie, D. J., Christiansen, E., Starlin, R., Little, R., & Stanley, S. (2001) · Clinical Infectious Diseases · doi:10.1086/319986 · Cited by 113
Cited by
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
“In a small number of patients, linezolid was effective therapy of vancomycin-resistant E faecium IE.(174) Birmingham et al(202) reported cure in 17 of 22 courses of therapy (77%) for E faecium IE.”
BackgroundDissemination and publication of research findings: an updated review of related biases
Song, F., Parekh, Hooper, L., Loke, Y., Ryder, J., Sutton, A., Hing, C., Kwok, C., Pang, C., & Harvey, I. (2010) · Health Technology Assessment · doi:10.3310/hta14080 · Cited by 1,039
Linezolid: a review of its properties, function, and use in critical care
Hashemian, S. M., Farhadi, T., & Ganjparvar, M. (2018) · Drug Design, Development and Therapy · doi:10.2147/dddt.s164515 · Cited by 459
“7% of patients, while the rest received a combination therapy.(30) Linezolid has been reported to be very effective in the treatment of ventilator-associated pneumonia and catheterrelated bacteremia, and hence, it is reasonable to use linezolid in the intensive care unit (ICU).”
BackgroundHolland, T. L., Baddour, L. M., Bayer, A. S., Hoen, B., Miro, J. M., & Fowler, V. G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.59 · Cited by 406
Management of multidrug-resistant enterococcal infections
Arias, C. A., Contreras, G. A., & Murray, B. E. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03214.x · Cited by 388
“apy in this study [48].”
Emergence and management of drug-resistant enterococcal infections
Arias, C. A., & Murray, B. E. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.5.637 · Cited by 294
Enterococcal Infection—Treatment and Antibiotic Resistance
Kristich, C. J., Rice, L. B., & Arias, C. A. (2014) · Europe PMC (PubMed Central) · Cited by 315
Clinical management of Staphylococcus aureus bacteraemia
Thwaites, G. E., Edgeworth, J. D., Gkrania-Klotsas, E., Kirby, A., Tilley, R., Török, M. E., Walker, S., Wertheim, H. F., Wilson, P., & Llewelyn, M. J. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70285-1 · Cited by 261
Linezolid pharmacokinetics and pharmacodynamics in clinical treatment
Dryden, M. S. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr072 · Cited by 198
Enterococcal Disease, Epidemiology, and Implications for Treatment
Higuita, N. I. A., & Huycke, M. M. (2014) · Europe PMC (PubMed Central) · Cited by 214
JCS 2017 Guideline on Prevention and Treatment of Infective Endocarditis
Nakatani, S., Ohara, T., Ashihara, K., Izumi, C., Iwanaga, S., Eishi, K., Okita, Y., Daimon, M., Kimura, T., Toyoda, K., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0549 · Cited by 179
Staphylococcus aureus (Including Staphylococcal Toxic Shock)
QUE, Y.-A., & MOREILLON, P. (2010) · Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases · doi:10.1016/b978-0-443-06839-3.00195-8 · Cited by 172
Staphylococcus aureus Bloodstream Infections: Definitions and Treatment
Corey, G. R. (2009) · Clinical Infectious Diseases · doi:10.1086/598186 · Cited by 166
Falagas, M. E., Siempos, I. I., & Vardakas, K. Z. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70312-2 · Cited by 166
Self-citationClinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones
Roger, C., Roberts, J. A., & Müller, L. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0601-x · Cited by 149
Vancomycin-Associated Nephrotoxicity: Grave Concern or Death by Character Assassination?
Hazlewood, K. A., Brouse, S. D., Pitcher, W. D., & Hall, R. G. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.05.031 · Cited by 154
McDonald, E. G., Aggrey, G., Aslan, A. T., Casias, M., Cortes-Penfield, N. W., Dong, M. Q., Egbert, S., Footer, B. W., Isler, B., King, M. A., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.26366 · Cited by 139
Improved understanding of factors driving methicillin-resistant Staphylococcus aureus epidemic waves
Otto, M. J., & Chatterjee (2013) · Clinical Epidemiology · doi:10.2147/clep.s37071 · Cited by 136
“107 Although vancomycin is inferior to β -lactam drugs 108 in terms of potency in sterilizing the blood, 109,110 and toxic effects to kidneys, 111 it is the preferred drug for the treatment of MRSA infections.”
Emerging Options for Treatment of Invasive, Multidrug‐Resistant Staphylococcus aureus Infections
Drew, R. H. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.2.227 · Cited by 116
Linezolid for the Treatment of Patients with Central Nervous System Infection
Ntziora, F., & Falagas, M. E. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1h307 · Cited by 112
Self-citationNew antimicrobial agents as therapy for resistant gram-positive cocci
Lentino, J. R., Narita, M., & Yu, V. L. (2007) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-007-0389-y · Cited by 121
“Based on 23 case reports and 3 case series, a total of 63% (21/33) of patients with endocarditis were cured with linezolid [94].”
BackgroundGalar, A., Weil, A. A., Dudzinski, D. M., Muñóz, P., & Siedner, M. J. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00041-18 · Cited by 103
“Additional efficacy and tolerability data are required to better support the use of linezolid for PVE (180).”
BackgroundSpellberg, B. J., Chambers, H. F. “., Musher, D. M., Walsh, T., & Bayer, A. S. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0555 · Cited by 96
Fraimow, H. S., & Tsigrelis, C. (2010) · Critical Care Clinics · doi:10.1016/j.ccc.2010.11.002 · Cited by 106
“first-line therapy for bacteremia, but has been successfully used in salvage therapy for bacteremia and even endocarditis.(56,57)”
MethodWatkins, R., Lemonovich, & File, T. M. (2012) · Core evidence · doi:10.2147/ce.s33430 · Cited by 87
“74 Five of the eight were cured, including the patient with the prosthetic valve.”
Clinical update on linezolid in the treatment of Gram-positive bacterial infections
Gould, K. (2012) · Infection and Drug Resistance · doi:10.2147/idr.s25890 · Cited by 98
“109–111 Falagas et al carried out a systematic review of the use of linezolid in the treatment of endocarditis, either as a single agent or in combination with other antibiotics.(112) Results from 33 patients were included, most with MRSA or VISA.”
Linezolid for the treatment of adults with bone and joint infections
Falagas, M. E., Siempos, I. Ι., Papagelopoulos, P. J., & Vardakas, K. Z. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.08.030 · Cited by 87
Self-citationTreatment of Methicillin-Resistant Staphylococcus aureus: Vancomycin and Beyond
Holmes, N. E., Tong, S. Y. C., Davis, J. S., & van Hal, S. J. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0034-1397040 · Cited by 93
Basarab, G. S., Doig, P. C., Galullo, V., Kern, G., Kimzey, A. L., Kutschke, A., Newman, J. P., Morningstar, M., Mueller, J. P., Otterson, L. G., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00863 · Cited by 78
Treatment of Enterococcus faecalis Infective Endocarditis: A Continuing Challenge
Hidalgo, L. H., Fernández-Rubio, B., Márquez, R. L., López-Cortés, L. E., Gil-Navarro, M. V., & de Alarcón, A. (2023) · Antibiotics · doi:10.3390/antibiotics12040704 · Cited by 81
Falagas, M. E., Giannopoulou, K., Ntziora, F., & Vardakas, K. Z. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm137 · Cited by 78
Self-citationTedizolid (TR-701): a new oxazolidinone with enhanced potency
Kanafani, Z. A., & Corey, G. R. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.660250 · Cited by 73
Freling, S., Wald‐Dickler, N., Banerjee, J., Canamar, C. P., Tangpraphaphorn, S., Bruce, D. N., Davar, K., Dominguez, F., Norwitz, D., Krishnamurthi, G., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad119 · Cited by 69
Gudiol, F., Aguado, J. M., Almirante, B., Bouza, E., Cercenado, E., Domínguez, M. Á., Gasch, O., Lora-Tamayo, J., Miró, J. M., Palomar, M., et al. (2015) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2015.03.015 · Cited by 78
Swedish guidelines for diagnosis and treatment of infective endocarditis
Westling, K., Aufwerber, E., Ekdahl, C., Friman, G., Gårdlund, B., Julander, I., Olaison, L., Olesund, C., Rundström, H., Snygg‐Martin, U., et al. (2007) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540701534517 · Cited by 66
“Newer antibiotics such as linezolid [34] and daptomycin [35] are not recommended in general, but could be considered in case of resistance or allergy for treatment of IE caused by Gram-positive cocci.”
BackgroundSmith, J. R., Barber, K. E., Raut, A., & Rybak, M. J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00053-15 · Cited by 62
Ntziora, F., & Falagas, M. E. (2007) · PubMed · Cited by 58
Self-citationClinical experience with recently approved antibiotics
PATERSON, D. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.07.001 · Cited by 40
Katsouli, A., & Massad, M. G. (2013) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2012.10.044 · Cited by 61
“A systematic review from 1995 to 2006 was performed to assess the effectiveness and safety of linezolid for treatment [29].”
BackgroundMethodEnterococcal Endocarditis Revisited
Pericàs, J. M., Zboromyrska, Y., Cervera, C., Castañeda, X., Almela, M., García-de-la-Mària, C., Mestres, C. A., Falces, C., Quintana, E., Ninot, S. P. I., et al. (2015) · Future Microbiology · doi:10.2217/fmb.15.46 · Cited by 60
What’s New in the Treatment of Enterococcal Endocarditis?
Nigo, M., Munita, J. M., Arias, C. A., & Murray, B. E. (2014) · Current Infectious Disease Reports · doi:10.1007/s11908-014-0431-z · Cited by 59
Infective endocarditis with negative blood cultures
Naber, C. K., & Erbel, R. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.07.017 · Cited by 55
Antibacterial oxazolidinones: emerging structure–toxicity relationships
Renslo, A. R. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.10.26 · Cited by 51
Enterococcal Endocarditis: Can We Win the War?
Munita, J. M., Arias, C. A., & Murray, B. E. (2012) · Current Infectious Disease Reports · doi:10.1007/s11908-012-0270-8 · Cited by 54
“[78]; four of the included cases were caused by E.”
BackgroundBloem, A., Bax, H. I., Yusuf, E., & Verkaik, N. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081743 · Cited by 50
“8% received prior antibiotic treatment, and 24% underwent surgical intervention [100].”
BackgroundStaphylococcus aureus (Including Staphylococcal Toxic Shock Syndrome)
Que, Y., & Moreillon, P. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00196-x · Cited by 54
Benefit-Risk Assessment of Linezolid for Serious Gram-Positive Bacterial Infections
Falagas, M. E., & Vardakas, K. Z. (2008) · Drug Safety · doi:10.2165/00002018-200831090-00004 · Cited by 46
Self-citationThirot, H., Briquet, C., Frippiat, F., Jacobs, F., Holemans, X., Henrard, S., Tulkens, P. M., Spinewine, A., & Bambeke, F. V. (2021) · Antibiotics · doi:10.3390/antibiotics10050530 · Cited by 44
“It has also shown to be of interest in the treatment of difficult-to-treat infections by multiresistant pathogens, like endocarditis [5] or osteomyelitis [6].”
BackgroundSipahi, O. R., Bardak, S., Turhan, T., Arda, B., Pullukcu, H., Ruksen, M., Aydemir, S., Dalbasti, T., Yurtseven, T., Zileli, M., et al. (2011) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365548.2011.585177 · Cited by 41
Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia
Gudiol, C., Cuervo, G., Shaw, E., Pujol, M., & Carratalà, J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1403585 · Cited by 62
Garzoni, C., & Vergidis, P. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12098 · Cited by 41
Wang, J., Tang, H.-J., Hsieh, P., Chiu, F., Chen, Y., Chang, M.-C., Huang, C.-T., Liu, C.-P., Lau, Y.-J., Hwang, K., et al. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.03.010 · Cited by 39
Linezolid for the treatment of drug-resistant infections
Herrmann, D. J., Peppard, W., Ledeboer, N. A., Theesfeld, M., Weigelt, J. A., & Buechel, B. J. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.6.825 · Cited by 43
Linezolid: effectiveness and safety for approved and off-label indications
Vardakas, K. Z., Ntziora, F., & Falagas, M. E. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.14.2381 · Cited by 39
Self-citationLinezolid: safety and efficacy in special populations
Gould, F. K. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr071 · Cited by 35
Pereira, M. R., Rana, M. M., & Practice, T. A. I. C. O. (2019) · Clinical Transplantation · doi:10.1111/ctr.13611 · Cited by 35
Vardakas, K. Z., Mavros, M. N., Roussos, N. S., & Falagas, M. E. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2011.12.011 · Cited by 34
Self-citationNew antibiotics: optimal use in current clinical practice
Karageorgopoulos, D. E., & Falagas, M. E. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(09)70569-2 · Cited by 36
“The relevant clinical evidence is scarce [34], and mixed findings have been reported [10].”
BackgroundInfluentialSelf-citationProsthetic valve endocarditis: state of the heart
Nagpal, A., Sohail, M. R., & Steckelberg, J. M. (2012) · Clinical Investigation · doi:10.4155/cli.12.70 · Cited by 31
Association of Pharmacokinetic and Pharmacodynamic Aspects of Linezolid with Infection Outcome
Vardakas, K. Z., Kioumis, I. P., & Falagas, M. E. (2009) · Current Drug Metabolism · doi:10.2174/138920009787048446 · Cited by 31
Self-citationXu-hong, Y., Falagas, M. E., Dong, W., Karageorgopoulos, D. E., De-feng, L., & Wang, R. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2014.5 · Cited by 29
Self-citationUpdate on the safety of linezolid
Metaxas, E. I., & Falagas, M. E. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903049706 · Cited by 29
“Examples of off-label indications of linezolid in adults are endocarditis with or without bacteremia [17,18], CNS infections [19] and bone and joint infections [20,21].”
BackgroundSelf-citationLinezolid for endocarditis: a case series of 14 patients
Tascini, C., Bongiorni, M. G., Doria, R., Polidori, M. C., Iapoce, R., Fondelli, S., Tagliaferri, E., Soldati, E., Paolo, A. D., Leonildi, A., et al. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq506 · Cited by 27
Westphal, N., Plicht, B., & Naber, C. K. (2009) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2009.0481 · Cited by 38
Yazaki, M., Oami, T., Nakanishi, K., Hase, R., & Watanabe, H. (2018) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2018.02.006 · Cited by 26
Novel pharmaceutical molecules against emerging resistant gram-positive cocci
Manfredi, R., & Sabbatani, S. (2010) · The Brazilian Journal of Infectious Diseases · doi:10.1016/s1413-8670(10)70020-9 · Cited by 27
Improved long-term performance of pulsatile extracorporeal left ventricular assist device
Sasaoka, T., Kato, T., Komamura, K., Takahashi, A., Nakajima, I., Oda, N., Hanatani, A., Mano, A., Asakura, M., Hashimura, K., et al. (2010) · Journal of Cardiology · doi:10.1016/j.jjcc.2010.05.010 · Cited by 23
Advances in Antibacterial Therapy Against Emerging Bacterial Pathogens
Pournaras, S., Iosifidis, Ε., & Roilides, E. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2009.03.007 · Cited by 23
New therapeutic choices for infections caused by methicillin-resistant Staphylococcus aureus
Bouza, E. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.03091.x · Cited by 29
Daptomycin Use After Vancomycin-Induced Neutropenia in a Patient with Left-Sided Endocarditis
Mergenhagen, K. A., & Pasko, M. T. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k071 · Cited by 24
Oxazolidinonas, glucopéptidos y lipopéptidos cíclicos
Pigrau, C., & Almirante, B. (2009) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2009.02.004 · Cited by 32
Chang, J. H. T., Tasellari, A., Wagner, J. L., & Scheetz, M. H. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2275663 · Cited by 22
“Conversely, a case series [122] and systematic review of case reports [23] reported success rates ranging from 60% to 85%.”
BackgroundQuelles nouveautés en antibiothérapie ?
Cattoir, V., & Daurel, C. (2009) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2009.10.009 · Cited by 21
Diagnosis, treatment and prevention of infective endocarditis: Turkish consensus report-2019*
Yavuz, S. Ş., Akar, A. R., Aydoğdu, S., Deniz, D. B., Demir, H., Hazırolan, T., Ozatik, M. A., Özer, N., Sargın, M., Topçuoğlu, N., et al. (2020) · Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology · doi:10.5543/tkda.2020.89689 · Cited by 25
Infection of intravascular prostheses: how to treat other than surgery
Utili, R., Durante‐Mangoni, E., & Tripodi, M. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.06.028 · Cited by 21
Treatment ofStaphylococcus aureusinfections: new issues, emerging therapies and future directions
Bishop, E. J., & Howden, B. P. (2007) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.12.1.1 · Cited by 24
Entenza, J. M., Veloso, T. R., Vouillamoz, J., Giddey, M., Majcherczyk, P. A., & Moreillon, P. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00402-11 · Cited by 20
“aureus bacteremia has been disappointing (8), and its use against infective endocarditis is precluded by the fact that it is not bactericidal (16).”
BackgroundEmpiric Antibiotic Therapy of Nosocomial Bacterial Infections
Reddy, P. (2014) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000042 · Cited by 17
“Despite obvious concerns, it has been successfully used in salvage therapy for bacteremia and even endocarditis.(38) Linezolid is bactericidal for Streptococci and can be used in the management of serious bacteremic S.”
MethodCurrent challenges in treating MRSA: what are the options?
Ratnaraja, N., & Hawkey, P. M. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.5.601 · Cited by 25
In vitro vancomycin susceptibility amongst methicillin resistant Staphylococcus aureus
Chaudhari, C., Tandel, K., Grover, N., Bhatt, P., Sahni, A. K., Sen, S., & Prahraj, A. (2014) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2013.11.008 · Cited by 17
“(C.N. Chaudhari). ed Forces Medical Service 2008e2009 from 17 participating tertiary care hospitals from different parts of India.2 Vancomycin is treatment of choice for infections caused by MRSA.”
BackgroundInfluentialMethicillin-resistant Staphylococcus epidermidis (MRSE) endocarditis treated with linezolid
Mancino, P., Ucciferri, C., Falasca, K., Pizzigallo, E., & Vecchiet, J. (2007) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540701509915 · Cited by 16
“Limited available evidence about the efficacy of linezolid for the treatment of patients with endocarditis is present in the literature [7].”
BackgroundShort-term success, but long-term treatment failure with linezolid for enterococcal endocarditis
Berdal, J., & Eskesen, A. N. (2008) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540802087209 · Cited by 15
“Several papers have been published of successful treatment of endocarditis with linezolid, mostly case reports and case series [4].”
BackgroundCrass, R. L., Powell, K., & Huang, A. M. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.09.004 · Cited by 14
Treatment of Complicated Gram-Positive Bacteremia and Infective Endocarditis
Schellong, P., Joean, O., Pletz, M. W., Hagel, S., & Weis, S. (2024) · Drugs · doi:10.1007/s40265-024-02135-z · Cited by 13
Clinical Guideline for the Diagnosis and Treatment of Cardiovascular Infections
The Korean Society of Infectious Diseases, Korean Society for Chemotherapy, The Korean Society of Cardiology, & The Korean Society for Thoracic and Cardiovascular Surgery (2011) · Infection and Chemotherapy · doi:10.3947/ic.2011.43.2.129 · Cited by 13
Gold, H. S., & Pillai, S. K. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2008.10.008 · Cited by 17
Zapata, B., Alvarez, D. N., Farah, S., García-de-la-Maria, C., Miró, J. M., Sakoulas, G., Bayer, A. S., & Mishra, N. N. (2018) · Current Microbiology · doi:10.1007/s00284-018-1491-3 · Cited by 12
Current Evidence on Oral Antibiotics for Infective Endocarditis: A Narrative Review
Kobayashi, T., Ando, T., Streit, J. A., & Sekar, P. (2019) · Cardiology and Therapy · doi:10.1007/s40119-019-00148-4 · Cited by 12
Treatment of tricuspid valve endocarditis with daptomycin and linezolid therapy
Galanter, K. M., & Ho, J. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz101 · Cited by 11
Zhao, S., Zhang, W., Zhang, L., Zhang, J., Li, J., Si, L., Ding, Y., Li, M., & Song, Y. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s413452 · Cited by 11
“However, bone marrow suppression, neuropathy, nephrotoxicity, and other side effects of intravenous administration have reminded doctors to curtail vancomycin dose.(3,4) In this case, vancomycin was used initially according to the guidelines for management of IE caused by MRSA which lasted 27 days.”
BackgroundMartín-Galiano, A. J., Yuste, J., Cercenado, M. I., & de la Campa, A. G. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-652 · Cited by 11
“Moreover, these new drugs are associated with undesirable side effects [3,4] and may suffer inactivation in some parts of the body [5].”
Boumis, E., Gesu, G. P., Menichetti, F., Ranieri, V. M., Rinaldi, M., Suter, F., Nicastri, E., Lauria, F., Carosi, G., Moroni, M., et al. (2010) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2010.05.006 · Cited by 12
“Falagas et al.25 reported a series of 19 patients with endocarditis treated with daptomycin.”
BackgroundMethodInfluentialResistant pathogen-associated skin and skin-structure infections: antibiotic options
Curcio, D. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.10.87 · Cited by 11
Compassionate Use of Linezolid for Adult Taiwanese Patients with Bone and Joint Infections
Lu, P., Wang, J., Chen, C., Chen, W., Chen, T., Hwang, Y.-C., & Chang, S. (2010) · Chemotherapy · doi:10.1159/000317752 · Cited by 11
“The thrombocytopenia rate of 15p in endocarditis patients receiving linezolid therapy is also evident, suggesting that the frequency of adverse effects could be higher when linezolid is used for long durations [”
BackgroundYavuz, S. Ş., Akar, A., Aydoğdu, S., Berzeg-Deniz, D., Demir, H., Hazırolan, T., Özatık, M. A., Özer, N., Sarğın, M., Topçuoğlu, N., et al. (2020) · Turkish Journal of Thoracic and Cardiovascular Surgery · doi:10.5606/tgkdc.dergisi.2020.01954 · Cited by 13
Linezolid for patients with neutropenia: are bacteriostatic agents appropriate?
Rafailidis, P. I., Kouranos, V., Christodoulou, C., & Falagas, M. E. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.11 · Cited by 10
Self-citationInfections associated with implanted medical devices
Millar, M. R., & Wareham, D. W. (2010) · Elsevier eBooks · doi:10.1016/b978-0-7020-4064-1.00042-7 · Cited by 11
Infectious diseases, tropical medicine and sexually transmitted infection
(2009) · Elsevier eBooks · doi:10.1016/b978-0-7020-2993-6.00009-2 · Cited by 9
Jasovich, A., Ganaha, M. C., Ebi, C., García, R., Blanco, M. Á. R., & Lopardo, H. Á. (2008) · PubMed · Cited by 10
Metadata
- Authors
- Falagas, M. E.
- Affiliations
- Henry Dunant Hospital (GR)
- Corresponding author
- Falagas, M. E.
- ORCID
- Falagas, M. E.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-05-30
- Volume
- 58
- Issue
- 2
- Pages
- 273-280
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2132751055
- Semantic Scholar
- 545a043e5b82976db958f7b3ba6dd6b97427306d
- Cited by
- 167
- References
- 43
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 4 · 2023: 10 · 2022: 1 · 2021: 2 · 2020: 4 · 2019: 6 · 2018: 4 · 2017: 6 · 2016: 4 · 2015: 12 · 2014: 11 · 2013: 3 · 2012: 10
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Antimicrobial Chemotherapy (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Surgery › Orthopedic Infections and Treatments
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Keywords
- linezolid, infective endocarditis, oxazolidinones, methicillin-resistant Staphylococcus aureus, vancomycin-intermediate Staphylococcus aureus, prosthetic valve endocarditis, bacteriostatic antibiotics, treatment efficacy, mortality, thrombocytopenia, combination antibiotic therapy
- MeSH terms
- Linezolid, Acetamides, Anti-Bacterial Agents, Endocarditis, Bacterial, Humans, Gram-Positive Bacterial Infections, Oxazolidinones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.